• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Celebrex (celecoxib) Dec 2004

Audience: Rheumatologists and other healthcare professionals

FDA notified healthcare professionals that, based on emerging information, including preliminary reports from one of several long term National Institutes of Health (NIH) prevention studies, the risk of cardiovascular events may be increased in patients receiving Celebrex. FDA is analyzing all available information from these studies to determine whether additional regulatory action is needed.

[December 17, 2004 - Drug Information Page - FDA]